The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|January 23, 2020
KOEHLER eClinical Expands in Germany
Advertisement
Koehler eClinical, a specialty contract research organization, is excited to announce that due to growth and high customer loyalty, its expansion continues with the opening of new offices in Mannheim, Germany effective January 2020.
The Mannheim office will support the growth in our core business area biostatistics and programming, with an initial team of 5 Biostatisticians and Statistical Programmers that come with a track record of having worked successfully together for years at Prometris GmbH.
“We are excited to expand our biometrics division with this very experienced group from Prometris, who wished to continue working together as a team, and are also particularly grateful to the Prometris management for their dedicated support in making this possible.” said Dr. Antal K. Hajos, CEO of Koehler eClinical. “We are pleased that the former Prometris Biostatistics Department has found a good new home together at Koehler eClinical.”, says Steffen Koenig, CRO of Prometris and IST GmbH.
The opening of the new Mannheim office, the 4thlocation of Koehler eClinical offices after Berlin, Constance and the headquarter office in Freiburg, follows the management handover in July last year to Michael Pfitzenmaier and Dr. Antal K. Hajos as new CEOs by Dr. Manfred Köhler, who remains as sole owner and Chair of the Board.
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where AI Governance in Clinical Development Falls Short
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5